ReviewCold Spring Harbor perspectives in medicine2014
Toward a unified biosignature for tuberculosis.
Review in Cold Spring Harbor perspectives in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Is interleukin-2 an optimal marker for diagnosing tuberculosis infection? A systematic review and meta-analysis.Annals of medicine · 2020Pooled it
- Pooled it
- A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2019Trial
- Host Plasma Protein Biomarkers for Tuberculosis Disease Screening in Febrile Adults in Tanzania.The Journal of infectious diseases · 2026Article
- Identification of host biomarkers from dried blood spots for monitoring treatment response in extrapulmonary tuberculosis.Scientific reports · 2023Article
- Plasma CXCL8 and MCP-1 as surrogate plasma biomarkers of latent tuberculosis infection among household contacts-A cross-sectional study.PLOS global public health · 2023Article
- Alterations of lipid-related genes during anti-tuberculosis treatment: insights into host immune responses and potential transcriptional biomarkers.Frontiers in immunology · 2023Article
- The spectrum of tuberculosis described as differential DNA methylation patterns in alveolar macrophages and alveolar T cells.Clinical epigenetics · 2022Article
- Metabolites enhance innate resistance to human Mycobacterium tuberculosis infection.JCI insight · 2022Article
- Development and Validation of a Parsimonious Tuberculosis Gene Signature Using the digital NanoString nCounter Platform.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Diagnosis of pulmonary tuberculosis via identification of core genes and pathways utilizing blood transcriptional signatures: a multicohort analysis.Respiratory research · 2022Article
- Etiopathogenesis, Challenges and Remedies Associated With Female Genital Tuberculosis: Potential Role of Nuclear Receptors.Frontiers in immunology · 2020Review
- Article
- Immune Biomarkers for Diagnosis and Treatment Monitoring of Tuberculosis: Current Developments and Future Prospects.Frontiers in microbiology · 2019Review
- Metabolite changes in blood predict the onset of tuberculosis.Nature communications · 2018Article
- Screening and identification of a six-cytokine biosignature for detecting TB infection and discriminating active from latent TB.Journal of translational medicine · 2018Article
- Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.The Lancet. Infectious diseases · 2018Review
- Predicting susceptibility to tuberculosis based on gene expression profiling in dendritic cells.Scientific reports · 2017Article
- Unbiased Identification of Blood-based Biomarkers for Pulmonary Tuberculosis by Modeling and Mining Molecular Interaction Networks.EBioMedicine · 2017Article
- Concise gene signature for point-of-care classification of tuberculosis.EMBO molecular medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate and rapid diagnosis of active tuberculosis (TB) disease is still hampered by inadequate tools. Although current assays relying on single-marker readouts mostly display inadequate sensitivity and/or specificity, host-related multimarker signatures are especially poorly developed. As a consequence, research programs have been initiated to search for combinations of markers-so-called biosignatures with superior performance. Many such investigations harness high-throughput platforms to analyze the host response during infection and disease. A major challenge for these activities is the analysis of vast amounts of data produced. Specialized bioinformatic tools are being applied to identify the most robust biosignatures for classification of exposed and diseased individuals and prognosis of risk of disease in endemic areas. Validation of the most promising biosignatures in ongoing multicohort studies will bring us a step closer to the identification of an accurate unified signature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.